A subunit gIV vaccine, produced by transfected mammalian cells in culture, induces mucosal immunity against bovine herpesvirus-1 in cattle
A truncated version of bovine herpesvirus-1 (BHV-1) glycoprotein 1 V (tgIV V) was produced in a novel, non-destructive expression system based upon regulation of gene expression by the bovine heat-shock protein 70A (hsp70) gene promoter in Madin Dal-by bovine kidney (MDBK) cells. In this system, up...
Gespeichert in:
| Veröffentlicht in: | Vaccine 1994, Vol.12 (14), p.1295-1302 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1302 |
|---|---|
| container_issue | 14 |
| container_start_page | 1295 |
| container_title | Vaccine |
| container_volume | 12 |
| creator | van Drunen Littel-van den Hurk, S. Van Donkersgoed, J. Kowalski, J. van den Hurk, J.V. Harland, R. Babiuk, L.A. Zamb, T.J. |
| description | A truncated version of bovine herpesvirus-1 (BHV-1) glycoprotein 1 V (tgIV V) was produced in a novel, non-destructive expression system based upon regulation of gene expression by the bovine heat-shock protein 70A (hsp70) gene promoter in Madin Dal-by bovine kidney (MDBK) cells. In this system, up to 20 μg ml
−1 of secreted tgIV, which is equivalent to the yield from 4 × 10
6 cells, was produced daily over a period of up to 18 days. Different doses of tgIV were injected intramuscularly into seronegative calves. Virus-neutralizing antibodies were induced by all doses of tgIV, both in the serum and in the nasal superficial mucosa. However, the low dose (2.3 μg) induced significantly (
p < 0.05) lower antibody titres than the medium (7 μg) and high (21 μg) doses. The medium and high doses of tgIV conferred protection from BHV-1 infection, as demonstrated by a significant (
p < 0.05) reduction in clinical signs of respiratory disease and virus shedding in the nasal secretions postchallenge. However, the 2.3,ug group, although partially protected, was not significantly (
p > 0.05) different from the placebo group. This study demonstrated the potential of an intramuscularly administered tgIV subunit vaccine to induce mucosal immunity to BHV-1 using an economic protein production system and an acceptable vaccine formulation. In addition, a strong correlation was observed between neutralizing antibodies in the serum and nasal superficial mucosa, virus shedding and clinical disease. Thus, serum neutralizing antibody levels in tgIV-immunized animals may be a good prognosticator of protection from BHV-1 infection and disease. |
| doi_str_mv | 10.1016/S0264-410X(94)80055-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77757078</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X94800555</els_id><sourcerecordid>16761175</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-6bd573dce31cb397df287c804de935444650eb59e2da06cc089609e36b238b13</originalsourceid><addsrcrecordid>eNqFkUuLFDEUhYMoYzv6EwayEFGwNKnKo2olw-BjYMCFg7gLedwaI_VocysN_Rf81aa6m97OKgn3nJOcfIRccfaBM64-_mC1EpXg7NfbTrxrGZOykk_Ihre6qWrJ26dkc5Y8Jy8Q_7Aianh3QS50K1XdiQ35d00xuzzFhT7c_qQ7632c4D3dpjlkD4G6PV2SnbAHv5TjaMfRDtFO1MMwII1lk4clp-KJ02pBOmY_ox1oHMc1eE_tg40TLtTNuxJOf0PaAu5iyljxQ4JdlgFekme9HRBendZLcv_l8_3Nt-ru-9fbm-u7youaLZVyQeomeGi4d02nQ1-32rdMBOgaKYRQkoGTHdTBMuU9azvFOmiUq5vW8eaSvDnGlop_M-BixohrGTvBnNForaVmun1UyJVWnGtZhPIo9GlGTNCbbYqjTXvDmVlZmQMrs4IwnTAHVmb1XZ0uyG6EcHad4JT569PcordDXzD4iGeZKJAlWwt9OsqgfNouQjLoI0wFXkwFmglzfOQh_wG9pLJv</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16761175</pqid></control><display><type>article</type><title>A subunit gIV vaccine, produced by transfected mammalian cells in culture, induces mucosal immunity against bovine herpesvirus-1 in cattle</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>van Drunen Littel-van den Hurk, S. ; Van Donkersgoed, J. ; Kowalski, J. ; van den Hurk, J.V. ; Harland, R. ; Babiuk, L.A. ; Zamb, T.J.</creator><creatorcontrib>van Drunen Littel-van den Hurk, S. ; Van Donkersgoed, J. ; Kowalski, J. ; van den Hurk, J.V. ; Harland, R. ; Babiuk, L.A. ; Zamb, T.J.</creatorcontrib><description>A truncated version of bovine herpesvirus-1 (BHV-1) glycoprotein 1 V (tgIV V) was produced in a novel, non-destructive expression system based upon regulation of gene expression by the bovine heat-shock protein 70A (hsp70) gene promoter in Madin Dal-by bovine kidney (MDBK) cells. In this system, up to 20 μg ml
−1 of secreted tgIV, which is equivalent to the yield from 4 × 10
6 cells, was produced daily over a period of up to 18 days. Different doses of tgIV were injected intramuscularly into seronegative calves. Virus-neutralizing antibodies were induced by all doses of tgIV, both in the serum and in the nasal superficial mucosa. However, the low dose (2.3 μg) induced significantly (
p < 0.05) lower antibody titres than the medium (7 μg) and high (21 μg) doses. The medium and high doses of tgIV conferred protection from BHV-1 infection, as demonstrated by a significant (
p < 0.05) reduction in clinical signs of respiratory disease and virus shedding in the nasal secretions postchallenge. However, the 2.3,ug group, although partially protected, was not significantly (
p > 0.05) different from the placebo group. This study demonstrated the potential of an intramuscularly administered tgIV subunit vaccine to induce mucosal immunity to BHV-1 using an economic protein production system and an acceptable vaccine formulation. In addition, a strong correlation was observed between neutralizing antibodies in the serum and nasal superficial mucosa, virus shedding and clinical disease. Thus, serum neutralizing antibody levels in tgIV-immunized animals may be a good prognosticator of protection from BHV-1 infection and disease.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/S0264-410X(94)80055-5</identifier><identifier>PMID: 7856294</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Animals ; Antibodies, Viral - biosynthesis ; Antibodies, Viral - blood ; Biological and medical sciences ; Blotting, Western - veterinary ; Bovine herpesvirus-I ; Cattle ; Cattle Diseases - immunology ; Cattle Diseases - prevention & control ; Cell Line ; Enzyme-Linked Immunosorbent Assay - veterinary ; Fundamental and applied biological sciences. Psychology ; Herpesviridae Infections - immunology ; Herpesviridae Infections - prevention & control ; Herpesviridae Infections - veterinary ; Herpesvirus 1, Bovine - immunology ; Microbiology ; mucosal immunity ; Nasal Mucosa - immunology ; Neutralization Tests - veterinary ; recombinant glycoprotein IV ; Transfection ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies ; Vaccines, Synthetic - administration & dosage ; Vaccines, Synthetic - biosynthesis ; Vaccines, Synthetic - immunology ; Viral Proteins - administration & dosage ; Viral Proteins - biosynthesis ; Viral Proteins - immunology ; Viral Vaccines - immunology ; Virology</subject><ispartof>Vaccine, 1994, Vol.12 (14), p.1295-1302</ispartof><rights>1994 Butterworth-Heinemann Ltd</rights><rights>1994 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-6bd573dce31cb397df287c804de935444650eb59e2da06cc089609e36b238b13</citedby><cites>FETCH-LOGICAL-c420t-6bd573dce31cb397df287c804de935444650eb59e2da06cc089609e36b238b13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0264-410X(94)80055-5$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,4024,27923,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4251501$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7856294$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van Drunen Littel-van den Hurk, S.</creatorcontrib><creatorcontrib>Van Donkersgoed, J.</creatorcontrib><creatorcontrib>Kowalski, J.</creatorcontrib><creatorcontrib>van den Hurk, J.V.</creatorcontrib><creatorcontrib>Harland, R.</creatorcontrib><creatorcontrib>Babiuk, L.A.</creatorcontrib><creatorcontrib>Zamb, T.J.</creatorcontrib><title>A subunit gIV vaccine, produced by transfected mammalian cells in culture, induces mucosal immunity against bovine herpesvirus-1 in cattle</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>A truncated version of bovine herpesvirus-1 (BHV-1) glycoprotein 1 V (tgIV V) was produced in a novel, non-destructive expression system based upon regulation of gene expression by the bovine heat-shock protein 70A (hsp70) gene promoter in Madin Dal-by bovine kidney (MDBK) cells. In this system, up to 20 μg ml
−1 of secreted tgIV, which is equivalent to the yield from 4 × 10
6 cells, was produced daily over a period of up to 18 days. Different doses of tgIV were injected intramuscularly into seronegative calves. Virus-neutralizing antibodies were induced by all doses of tgIV, both in the serum and in the nasal superficial mucosa. However, the low dose (2.3 μg) induced significantly (
p < 0.05) lower antibody titres than the medium (7 μg) and high (21 μg) doses. The medium and high doses of tgIV conferred protection from BHV-1 infection, as demonstrated by a significant (
p < 0.05) reduction in clinical signs of respiratory disease and virus shedding in the nasal secretions postchallenge. However, the 2.3,ug group, although partially protected, was not significantly (
p > 0.05) different from the placebo group. This study demonstrated the potential of an intramuscularly administered tgIV subunit vaccine to induce mucosal immunity to BHV-1 using an economic protein production system and an acceptable vaccine formulation. In addition, a strong correlation was observed between neutralizing antibodies in the serum and nasal superficial mucosa, virus shedding and clinical disease. Thus, serum neutralizing antibody levels in tgIV-immunized animals may be a good prognosticator of protection from BHV-1 infection and disease.</description><subject>Animals</subject><subject>Antibodies, Viral - biosynthesis</subject><subject>Antibodies, Viral - blood</subject><subject>Biological and medical sciences</subject><subject>Blotting, Western - veterinary</subject><subject>Bovine herpesvirus-I</subject><subject>Cattle</subject><subject>Cattle Diseases - immunology</subject><subject>Cattle Diseases - prevention & control</subject><subject>Cell Line</subject><subject>Enzyme-Linked Immunosorbent Assay - veterinary</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Herpesviridae Infections - immunology</subject><subject>Herpesviridae Infections - prevention & control</subject><subject>Herpesviridae Infections - veterinary</subject><subject>Herpesvirus 1, Bovine - immunology</subject><subject>Microbiology</subject><subject>mucosal immunity</subject><subject>Nasal Mucosa - immunology</subject><subject>Neutralization Tests - veterinary</subject><subject>recombinant glycoprotein IV</subject><subject>Transfection</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies</subject><subject>Vaccines, Synthetic - administration & dosage</subject><subject>Vaccines, Synthetic - biosynthesis</subject><subject>Vaccines, Synthetic - immunology</subject><subject>Viral Proteins - administration & dosage</subject><subject>Viral Proteins - biosynthesis</subject><subject>Viral Proteins - immunology</subject><subject>Viral Vaccines - immunology</subject><subject>Virology</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUuLFDEUhYMoYzv6EwayEFGwNKnKo2olw-BjYMCFg7gLedwaI_VocysN_Rf81aa6m97OKgn3nJOcfIRccfaBM64-_mC1EpXg7NfbTrxrGZOykk_Ihre6qWrJ26dkc5Y8Jy8Q_7Aianh3QS50K1XdiQ35d00xuzzFhT7c_qQ7632c4D3dpjlkD4G6PV2SnbAHv5TjaMfRDtFO1MMwII1lk4clp-KJ02pBOmY_ox1oHMc1eE_tg40TLtTNuxJOf0PaAu5iyljxQ4JdlgFekme9HRBendZLcv_l8_3Nt-ru-9fbm-u7youaLZVyQeomeGi4d02nQ1-32rdMBOgaKYRQkoGTHdTBMuU9azvFOmiUq5vW8eaSvDnGlop_M-BixohrGTvBnNForaVmun1UyJVWnGtZhPIo9GlGTNCbbYqjTXvDmVlZmQMrs4IwnTAHVmb1XZ0uyG6EcHad4JT569PcordDXzD4iGeZKJAlWwt9OsqgfNouQjLoI0wFXkwFmglzfOQh_wG9pLJv</recordid><startdate>1994</startdate><enddate>1994</enddate><creator>van Drunen Littel-van den Hurk, S.</creator><creator>Van Donkersgoed, J.</creator><creator>Kowalski, J.</creator><creator>van den Hurk, J.V.</creator><creator>Harland, R.</creator><creator>Babiuk, L.A.</creator><creator>Zamb, T.J.</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>7T7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>1994</creationdate><title>A subunit gIV vaccine, produced by transfected mammalian cells in culture, induces mucosal immunity against bovine herpesvirus-1 in cattle</title><author>van Drunen Littel-van den Hurk, S. ; Van Donkersgoed, J. ; Kowalski, J. ; van den Hurk, J.V. ; Harland, R. ; Babiuk, L.A. ; Zamb, T.J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-6bd573dce31cb397df287c804de935444650eb59e2da06cc089609e36b238b13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Animals</topic><topic>Antibodies, Viral - biosynthesis</topic><topic>Antibodies, Viral - blood</topic><topic>Biological and medical sciences</topic><topic>Blotting, Western - veterinary</topic><topic>Bovine herpesvirus-I</topic><topic>Cattle</topic><topic>Cattle Diseases - immunology</topic><topic>Cattle Diseases - prevention & control</topic><topic>Cell Line</topic><topic>Enzyme-Linked Immunosorbent Assay - veterinary</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Herpesviridae Infections - immunology</topic><topic>Herpesviridae Infections - prevention & control</topic><topic>Herpesviridae Infections - veterinary</topic><topic>Herpesvirus 1, Bovine - immunology</topic><topic>Microbiology</topic><topic>mucosal immunity</topic><topic>Nasal Mucosa - immunology</topic><topic>Neutralization Tests - veterinary</topic><topic>recombinant glycoprotein IV</topic><topic>Transfection</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies</topic><topic>Vaccines, Synthetic - administration & dosage</topic><topic>Vaccines, Synthetic - biosynthesis</topic><topic>Vaccines, Synthetic - immunology</topic><topic>Viral Proteins - administration & dosage</topic><topic>Viral Proteins - biosynthesis</topic><topic>Viral Proteins - immunology</topic><topic>Viral Vaccines - immunology</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van Drunen Littel-van den Hurk, S.</creatorcontrib><creatorcontrib>Van Donkersgoed, J.</creatorcontrib><creatorcontrib>Kowalski, J.</creatorcontrib><creatorcontrib>van den Hurk, J.V.</creatorcontrib><creatorcontrib>Harland, R.</creatorcontrib><creatorcontrib>Babiuk, L.A.</creatorcontrib><creatorcontrib>Zamb, T.J.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van Drunen Littel-van den Hurk, S.</au><au>Van Donkersgoed, J.</au><au>Kowalski, J.</au><au>van den Hurk, J.V.</au><au>Harland, R.</au><au>Babiuk, L.A.</au><au>Zamb, T.J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A subunit gIV vaccine, produced by transfected mammalian cells in culture, induces mucosal immunity against bovine herpesvirus-1 in cattle</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>1994</date><risdate>1994</risdate><volume>12</volume><issue>14</issue><spage>1295</spage><epage>1302</epage><pages>1295-1302</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>A truncated version of bovine herpesvirus-1 (BHV-1) glycoprotein 1 V (tgIV V) was produced in a novel, non-destructive expression system based upon regulation of gene expression by the bovine heat-shock protein 70A (hsp70) gene promoter in Madin Dal-by bovine kidney (MDBK) cells. In this system, up to 20 μg ml
−1 of secreted tgIV, which is equivalent to the yield from 4 × 10
6 cells, was produced daily over a period of up to 18 days. Different doses of tgIV were injected intramuscularly into seronegative calves. Virus-neutralizing antibodies were induced by all doses of tgIV, both in the serum and in the nasal superficial mucosa. However, the low dose (2.3 μg) induced significantly (
p < 0.05) lower antibody titres than the medium (7 μg) and high (21 μg) doses. The medium and high doses of tgIV conferred protection from BHV-1 infection, as demonstrated by a significant (
p < 0.05) reduction in clinical signs of respiratory disease and virus shedding in the nasal secretions postchallenge. However, the 2.3,ug group, although partially protected, was not significantly (
p > 0.05) different from the placebo group. This study demonstrated the potential of an intramuscularly administered tgIV subunit vaccine to induce mucosal immunity to BHV-1 using an economic protein production system and an acceptable vaccine formulation. In addition, a strong correlation was observed between neutralizing antibodies in the serum and nasal superficial mucosa, virus shedding and clinical disease. Thus, serum neutralizing antibody levels in tgIV-immunized animals may be a good prognosticator of protection from BHV-1 infection and disease.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>7856294</pmid><doi>10.1016/S0264-410X(94)80055-5</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 1994, Vol.12 (14), p.1295-1302 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77757078 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Animals Antibodies, Viral - biosynthesis Antibodies, Viral - blood Biological and medical sciences Blotting, Western - veterinary Bovine herpesvirus-I Cattle Cattle Diseases - immunology Cattle Diseases - prevention & control Cell Line Enzyme-Linked Immunosorbent Assay - veterinary Fundamental and applied biological sciences. Psychology Herpesviridae Infections - immunology Herpesviridae Infections - prevention & control Herpesviridae Infections - veterinary Herpesvirus 1, Bovine - immunology Microbiology mucosal immunity Nasal Mucosa - immunology Neutralization Tests - veterinary recombinant glycoprotein IV Transfection Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies Vaccines, Synthetic - administration & dosage Vaccines, Synthetic - biosynthesis Vaccines, Synthetic - immunology Viral Proteins - administration & dosage Viral Proteins - biosynthesis Viral Proteins - immunology Viral Vaccines - immunology Virology |
| title | A subunit gIV vaccine, produced by transfected mammalian cells in culture, induces mucosal immunity against bovine herpesvirus-1 in cattle |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T05%3A05%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20subunit%20gIV%20vaccine,%20produced%20by%20transfected%20mammalian%20cells%20in%20culture,%20induces%20mucosal%20immunity%20against%20bovine%20herpesvirus-1%20in%20cattle&rft.jtitle=Vaccine&rft.au=van%20Drunen%20Littel-van%20den%20Hurk,%20S.&rft.date=1994&rft.volume=12&rft.issue=14&rft.spage=1295&rft.epage=1302&rft.pages=1295-1302&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/S0264-410X(94)80055-5&rft_dat=%3Cproquest_cross%3E16761175%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16761175&rft_id=info:pmid/7856294&rft_els_id=S0264410X94800555&rfr_iscdi=true |